SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
CDMO
--
0.00%
--
Laughing Water Capital H1 2020 Letter
Seeking Alpha · 5d ago
Avid Bioservices And Argonaut Manufacturing Services Enter Agreement To Offer Biotechnology And Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing And Drug Product Parenteral Manufacturing
Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics TUSTIN,
Benzinga · 6d ago
Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing
Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic TherapeuticsTUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWI
GlobeNewswire · 6d ago
Is Avid Bioservices, Inc. (CDMO) Going to Burn These Hedge Funds?
Insider Monkey · 07/05 23:34
How Much Of Avid Bioservices, Inc. (NASDAQ:CDMO) Do Insiders Own?
Simply Wall St. · 07/03 17:13
Analysts Say These 3 Stocks Are Their Top Picks for Post-Pandemic Gains
TipRanks · 07/02 18:11
Avid Bioservices (CDMO) Catches Eye: Stock Jumps 5.4%
Zacks · 07/01 13:30
How Avid Bioservices Beat Wall Street Estimates in Q4
Motley Fool · 07/01 12:02
Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options
Zacks · 07/01 04:36
Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 07/01 01:55
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments
GlobeNewswire · 06/30 21:05
Avid Bioservices Sees FY21 Sales Guidance Of $76M-$81M
Benzinga · 06/30 20:08
Avid Bioservices Q4 EPS $(0.11) Beats $(0.16) Estimate, Sales $12.60M Beat $8.50M Estimate
Avid Bioservices (NASDAQ:CDMO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 450 percent decrease over losses of $(0.02) per share from
Benzinga · 06/30 20:07
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020
TUSTIN, Calif., June 23, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
GlobeNewswire · 06/23 20:05
Avid Bioservices Names Nicholas Green As President And Chief Executive Officer
TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by
Benzinga · 06/23 12:11
Analysts Estimate Avid Bioservices (CDMO) to Report a Decline in Earnings: What to Look Out for
Zacks · 06/18 17:30
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif., June 03, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
GlobeNewswire · 06/03 20:05
Moderna Phase 2 Approved, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/10 12:34